Indivior PLC - Ordinary Shares (INDV)

Competitors to Indivior PLC - Ordinary Shares (INDV)

Alkermes Plc 

Alkermes actively competes with Indivior in the treatment of opioid use disorder with products like Vivitrol, which is designed to prevent relapse in people with alcohol or opioid dependence. Both companies focus on long-acting injectable formulations, although Alkermes emphasizes the use of Vivitrol in a broader context for alcohol dependence. Alkermes' established presence and experience with schizophrenia and depression also diversify their portfolios, giving them an edge in broader therapeutic areas.

Amgen Inc. 

While Amgen is predominantly focused on biotechnology and lifestyle-related metabolic disorders, their expertise in drug development and commercialization gives them a broader platform to support potentially new addiction treatments in the market. Indivior faces competition from established biotech companies like Amgen that could pivot towards addiction treatment, however, Amgen's scale and operational capabilities may lead to stronger research outcomes.

Catalyst Pharmaceuticals, Inc. 

Catalyst Pharmaceuticals has carved out a niche in the treatment of rare diseases related to addiction, offering their product Firdapse for myasthenia gravis alongside its efforts to expand its portfolio. While not a direct competitor in opioid dependence, their focus on developing innovative treatments for neurological conditions positions them as a potential challenger in the addiction treatment space. Their niche expertise in rare diseases could provide a strategic advantage.

Horizon Therapeutics plc

Horizon Therapeutics specializes in rare and rheumatic diseases but is expanding its portfolio, looking at neurological conditions that may involve addiction treatment. Their innovative approaches to drug discovery and patient-centered care play into the addiction sphere indirectly but can become a significant threat as they leverage their R&D efforts to address broader mental health and addiction issues. They possess a strategic advantage through continuous diversification.

Jazz Pharmaceuticals plc 

Jazz Pharmaceuticals competes with Indivior through its focus on sleep disorders, pain management, and mental health, bringing to market treatments that can overlap with anti-addiction therapies. Their broad portfolio, with significant investment in research and development, positions them strongly to innovate and diversify their approach. Jazz's financial resources allow them to potentially outpace competitors in bringing new therapies to market.